Not Yet Recruiting PHASE3 INTERVENTIONAL 2-arm
NCT07245680
COMMODITIES Trial: Initial Dual Oral Therapy vs Monotherapy in PAH With Cardiovascular Comorbidities (COMMODITIES)
Comparison of Initial Dual Oral COMbination Therapy to MOnotherapy in Pulmonary Arterial Hypertension With Cardiovascular comorbiDITIES
Sponsor: Assistance Publique - Hôpitaux de Paris
Interventions
Ambrisentan Placebo (Ambrisentan-matching) Tadalafil
Updated 1 time since 2025 Last updated: Nov 17, 2025 Started: Jan 15, 2026 Primary completion: Feb 14, 2029 Completion: Feb 14, 2029
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
Listed as NCT07245680, this PHASE3 trial focuses on Cardiovascular Disease (CVD) and Comorbidities and remains actively recruiting participants. Sponsored by Assistance Publique - Hôpitaux de Paris, it has been updated 1 time since 2026, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.
Status Flow
Change History
1 version recorded Not Yet Recruiting — PHASE3
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Assistance Publique - Hôpitaux de Paris
Data source: Assistance Publique - Hôpitaux de Paris
For direct contact, visit the study record on ClinicalTrials.gov .